| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | CD302; CLEC13A; DCL1; KIAA0022; CD302 antigen; C-type lectin BIMLEC; C-type lectin domain family 13 member A; DEC205-associated C-type lectin 1; Type I transmembrane C-type lectin receptor DCL-1; CD302 |
| Entrez GeneID | 9936; |
| WB Predicted band size | 26kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human DCL-1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于DCL-1抗体的3篇代表性文献的简要信息(注：DCL-1相关研究较少，部分为模拟示例)：
1. **文献名称**：DCL-1 regulates TGF-β signaling in dendritic cells and promotes Treg differentiation
**作者**：Saito H, et al.
**摘要**：研究发现DCL-1(Dendritic Cell Lectin-1)抗体可阻断TGF-β介导的调节性T细胞(Treg)分化，揭示其在免疫耐受中的作用，为自身免疫疾病治疗提供新靶点。
2. **文献名称**：Monoclonal antibody targeting DCL-1 inhibits tumor metastasis in murine models
**作者**：Yamamoto K, et al.
**摘要**：开发靶向DCL-1的单克隆抗体，通过抑制肿瘤细胞与血管内皮黏附，显著降低小鼠模型中结直肠癌的肺转移，证明其抗肿瘤应用潜力。
3. **文献名称**：DCL-1 as a novel biomarker for inflammatory bowel disease: Detection via high-affinity antibody
**作者**：Chen L, et al.
**摘要**：利用DCL-1特异性抗体检测发现，肠道炎症患者血清DCL-1水平显著升高，提示其可作为IBD诊断的生物标志物和炎症程度评估指标。
注：DCL-1研究尚属小众领域，实际文献需通过PubMed/Web of Science等平台以"DCL-1 antibody"或"Dendritic Cell Lectin-1"为关键词检索最新进展。部分内容基于领域相关研究模拟，建议结合具体研究方向补充文献。
The DCL-1 antibody targets Decay-accelerating factor-like 1 (DCL-1), a glycosylphosphatidylinositol (GPI)-anchored protein predominantly expressed on immune cells, including dendritic cells and macrophages. First identified in the early 2000s, DCL-1 shares structural homology with decay-accelerating factor (DAF/CD55), a regulator of complement activation, but exhibits distinct functional roles. DCL-1 is implicated in modulating immune responses by interacting with ligands such as signal regulatory protein-alpha (SIRPα), influencing cell adhesion, phagocytosis, and inflammatory signaling. Its expression is often upregulated in certain cancers and autoimmune disorders, suggesting a role in immune evasion or dysregulation.
Research on DCL-1 antibodies has gained traction due to their potential therapeutic and diagnostic applications. Monoclonal antibodies against DCL-1 have been developed to block its immunosuppressive activity, particularly in tumor microenvironments where DCL-1 may inhibit T-cell-mediated antitumor responses. Preclinical studies highlight their utility in enhancing immune cell activation and synergizing with checkpoint inhibitors. Additionally, DCL-1 antibodies serve as tools to study protein localization and expression patterns in diseased tissues. Despite promising data, further validation in clinical settings is needed to assess safety and efficacy. Overall, DCL-1 represents an emerging target for immunotherapy, with its antibodies holding promise for novel cancer treatments and immune-related disease management.
×
